Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$13 Mln
P/E Ratio
--
P/B Ratio
0.49
Industry P/E
--
Debt to Equity
0.18
ROE
-0.82 %
ROCE
-72.68 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-16.81 Mln
EBITDA
$-60.30 Mln
Net Profit
$-67.68 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
SAB Biotherapeutics (SABS)
| -62.18 | -10.87 | -59.69 | -70.59 | -63.20 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
SAB Biotherapeutics (SABS)
| -44.58 | 16.63 | -92.45 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,226.85 | 20.76 | 23.13 | |
| 296.28 | 9,219.66 | 24.15 | 58.42 | |
| 24.72 | 10,361.50 | -- | -28.77 | |
| 101.38 | 9,388.25 | 28.84 | 14.16 |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering... and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. Address: 777 W 41st St., Miami Beach, FL, United States, 33140 Read more
CEO & Executive Chairman
Mr. Samuel J. Reich
CEO & Executive Chairman
Mr. Samuel J. Reich
Headquarters
Miami Beach, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of SAB Biotherapeutics Inc (SABS) stood at $ 44 Mln as on 31-Dec-24
The share price of SAB Biotherapeutics Inc (SABS) is $1.44 (NASDAQ) as of 17-Apr-2025 16:00 EDT. SAB Biotherapeutics Inc (SABS) has given a return of -63.2% in the last 3 years.
SAB Biotherapeutics Inc (SABS) has a market capitalisation of $ 13 Mln as on 15-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of SAB Biotherapeutics Inc (SABS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the SAB Biotherapeutics Inc (SABS) and enter the required number of quantities and click on buy to purchase the shares of SAB Biotherapeutics Inc (SABS).
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. Address: 777 W 41st St., Miami Beach, FL, United States, 33140
The CEO & director of Mr. Samuel J. Reich. is SAB Biotherapeutics Inc (SABS), and CFO & Sr. VP is Mr. Samuel J. Reich.
There is no promoter pledging in SAB Biotherapeutics Inc (SABS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| SAB Biotherapeutics Inc. (SABS) | Ratios |
|---|---|
|
Return on equity(%)
|
-81.92
|
|
Operating margin(%)
|
-2603.1
|
|
Net Margin(%)
|
-2579.03
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of SAB Biotherapeutics Inc (SABS) was $0 Mln.
$0.05
(
